Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Efficacy of Recombinant Human G-CSF in Women With Unexplained Recurrent Miscarriage (GEM)

20 de julho de 2026 atualizado por: Lamiya Mohiyiddeen, Fakih IVF Fertility Center

A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Efficacy of Recombinant Human G-CSF in Women With Unexplained Recurrent Miscarriage After IVF With PGT-A Screened Euploid Embryo Transfer

Recurrent pregnancy loss (RPL), commonly referred to as recurrent miscarriage, affects approximately 1-2% of couples attempting to conceive. In nearly half of these cases, no definitive cause can be identified despite thorough clinical evaluation. A circumstance that is both distressing and disorienting for affected families, particularly in settings such as the United Arab Emirates (UAE), where childbearing carries significant personal and cultural weight.

One leading hypothesis is that the underlying problem may not lie with the embryo itself, but with the way the mother's immune system responds to a developing pregnancy. Under normal physiological conditions, the maternal body must establish immune tolerance toward an embryo that is genetically half-foreign in origin. In some women, this tolerance mechanism may be impaired, reducing the likelihood that a pregnancy will successfully implant and progress.

This study will evaluate whether granulocyte colony-stimulating factor (G-CSF) a naturally occurring substance that normally stimulates the production of immune cells can help address this issue by modulating an overactive immune response and enhancing the uterine environment's capacity to support pregnancy. Notably, the study will enroll only women whose embryos have undergone genetic testing and been confirmed to be chromosomally normal. This eliminates embryo quality as a contributing factor to pregnancy loss and allows for a clearer assessment of whether G-CSF itself influences outcomes.

Earlier small-scale studies, including preliminary work conducted at our own centre, have shown encouraging results. This new trial builds on that foundation by enrolling a larger cohort, comparing G-CSF against a placebo (an inactive comparison treatment), and evaluating a simpler route of administration; subcutaneous injection, rather than direct infusion into the uterus. Together, these design features aim to provide the most reliable evidence to date on whether this treatment can meaningfully help couples affected by unexplained recurrent pregnancy loss.

Visão geral do estudo

Descrição detalhada

Recurrent pregnancy loss (RPL) defined as two or more consecutive miscarriages before 20 weeks' gestation affects 1-2% of couples worldwide and remains one of the most distressing, poorly resolved conditions in reproductive medicine. In nearly half of cases, no definitive cause is identified. This burden is especially pronounced in the UAE and wider GCC region, where delayed childbearing and the strong sociocultural weight placed on fertility amplify the psychological, marital, and financial toll of unexplained RPL.

Despite decades of research, treatment remains largely empirical. Immune dysregulation is increasingly implicated as a central mechanism, with proposed pathways including aberrant natural killer (NK) cell activation, impaired regulatory T-cell expansion, inadequate decidualization, and an unfavorable Th1/Th17 cytokine profile, collectively compromising endometrial receptivity and embryo survival. However, most supporting studies have been small, uncontrolled, and unable to distinguish maternal immunological causes from embryo genetic abnormalities, leaving clinicians with few evidence-based options.

Granulocyte colony-stimulating factor (G-CSF), a hematopoietic cytokine with immunomodulatory and endometrial effects, has emerged as a promising candidate. Preclinical and early clinical data suggest it enhances endometrial proliferation and vascularization, supports folliculogenesis and oocyte competence, and promotes immune tolerance by expanding regulatory T-cells while reducing NK cell cytotoxicity. Small trials in both recurrent implantation failure and RPL populations have reported benefits in implantation and live birth rates, though results have been inconsistent - largely due to the same methodological limitations noted above, plus a failure to control for embryo aneuploidy as a confounder.

Our own retrospective pilot study of 19 patients receiving intrauterine G-CSF supports this rationale: 70.5% achieved a positive β-hCG, 66.7% progressed to ongoing pregnancy, and no adverse effects were observed. These findings demonstrate both feasibility and preliminary efficacy at our centre. However, intrauterine infusion is invasive, costly, and less patient-friendly; existing literature suggests subcutaneous administration may achieve comparable efficacy with greater convenience, but this route has not yet been evaluated in this specific population.

The GEM Trial is designed to resolve these open questions directly. By enrolling women with unexplained RPL undergoing IVF with preimplantation genetic testing for aneuploidy (PGT-A), the trial eliminates embryo chromosomal abnormality as a confounder, enabling a precise, mechanistically targeted test of the immunological hypothesis. It will be the first placebo-controlled, genetically controlled trial of G-CSF in this population, and the first to formally assess subcutaneous delivery.

If successful, the GEM Trial could establish a new standard of care for unexplained RPL offering a more convenient, evidence-based treatment option to thousands of couples and positioning the UAE as a global leader in reproductive immunology research.

Tipo de estudo

Intervencional

Inscrição (Estimado)

150

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

      • Abu Dhabi, Emirados Árabes Unidos
        • Recrutamento
        • Fakih IVF Fertility Centre LLC
        • Contato:
        • Contato:
        • Investigador principal:
          • Michael Fakih, MD
        • Investigador principal:
          • Lamiya Mohiyiddeen, MD, FRCOG
        • Investigador principal:
          • Yasmin Sajjad, MD, FRCOG

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion:

  1. Women aged 18-44 years
  2. ≥2 unexplained pregnancy losses
  3. Undergoing IVF with PGT-A tested embryos
  4. BMI 19-35 kg/m² 6.

Exclusion:

  1. Parental karyotype abnormalities
  2. Correctable uterine abnormalities
  3. Systemic autoimmune disease / thrombophilia
  4. Uncontrolled systemic illness (e.g. diabetes, infection)
  5. Previous G-CSF therapy
  6. Hypersensitivity to rhG-CSF or E. coli proteins
  7. HIV, malignancy within 5 years, or severe cardiovascular/respiratory history

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Recombinant G-CSF 130 mcg SC
Subcutaneous injection of Recombinant G-CSF daily from embryo transfer until 12 weeks' gestation
Subcutaneous injection of Recombinant G-CSF daily from embryo transfer until 12 weeks' gestation
Comparador de Placebo: Placebo Control: Placebo SC
Subcutaneous injection of placebo daily from embryo transfer until 12 weeks' gestation
Subcutaneous injection of Recombinant G-CSF daily from embryo transfer until 12 weeks' gestation

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Clinical pregnancy rate
Prazo: From enrollment to 16 weeks gestation
Clinical pregnancy confirmation by transvaginal ultrasound at 16 weeks' gestation.
From enrollment to 16 weeks gestation

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Live birth rate
Prazo: From enrollment to approximately 40 weeks' gestation.
From enrollment to approximately 40 weeks' gestation.
Ongoing Pregnancy Rate
Prazo: From 16 weeks to 34 weeks gestation.
16 - 34 weeks gestation by serial ultrasound.
From 16 weeks to 34 weeks gestation.
Early Pregnancy Loss rate
Prazo: From FET (Fetal Embryo Transfer) to 12 weeks gestation
Pregnancy loss confirmed by a transvaginal ultrasound.
From FET (Fetal Embryo Transfer) to 12 weeks gestation
Rate of Adverse pregnancy outcomes (APOs)
Prazo: From enrollment to approximately 40 weeks gestation
Rate of Miscarriage, stillbirth, neonatal outcomes (birth weight, NICU admission, congenital anomalies) and maternal outcomes assessed using several methods including transvaginal ultrasound and clinical assessment.
From enrollment to approximately 40 weeks gestation
Rate of Adverse events
Prazo: From enrollment up to approximately 40 weeks gestation (delivery)
Safety data including pregnancy related, fetal or maternal adverse events e.g. infections, cytopenias, hypersensitivity etc.
From enrollment up to approximately 40 weeks gestation (delivery)
Rate of immunogenicity
Prazo: From enrollment to up to approximately 40 weeks gestation (delivery)
Anti-drug antibody (ADA) formation (serology in subset).
From enrollment to up to approximately 40 weeks gestation (delivery)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

10 de julho de 2026

Conclusão Primária (Estimado)

10 de agosto de 2027

Conclusão do estudo (Estimado)

10 de outubro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

14 de julho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

20 de julho de 2026

Primeira postagem (Real)

24 de julho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

24 de julho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

20 de julho de 2026

Última verificação

1 de julho de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • FAKIH-2025-10
  • DOH/ADHRTC/2026/34566666666666 (Outro identificador: Department of Health Abu Dhabi)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever